,54 We, therefore, hypothesize that robust ADAR1-mediated editing of the MAVS transcript observed in DLBCL patients (Figure 2B) would provide an alternative, and RLR-independent way of signaling toward ISG/NF-κB pathway activation (Figure S5B). The gene discussed is MAVS; the disease is diffuse large B-cell lymphoma.